New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
09:55 EDTNUVA, NUVA, SYK, SYK, ZMH, ZMH, GMED, GMED, JNJ, JNJ, KTWO, KTWO, LDRH, LDRH, MDT, MDT, MZOR, MZORLeerink medical devices analyst holds an analyst/industry conference call
Medical Devices Analyst Newitter, along with J. Scott Price, M.D., an orthopedic surgeon, discusses industry trends and new products currently being used for the spine, including fixation devices from NUVA, on an Analyst/Industry conference call. Other companies including GMED, JNJ, KTWO, LDRH, MDT, MZOR, SYK and ZMH may be discussed on the Analyst/Industry conference call to be held on July 25 at 10:30 am.
News For GMED;JNJ;KTWO;LDRH;MDT;MZOR;NUVA;SYK;ZMH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2015
07:10 EDTMDTMedtronic study detects gene associated with sudden cardiac death
Subscribe for More Information
August 27, 2015
19:49 EDTJNJJohnson & Johnson to open shared services headquarters in Florida
Subscribe for More Information
August 25, 2015
13:01 EDTJNJJ&J unit to sell Splenda brand to Heartland Food, terms not disclosed
Subscribe for More Information
09:07 EDTMDTMedtronic to acquire Twelve for $458M
In support of the company's therapy innovation strategy, Medtronic announced that it has signed a definitive agreement to acquire Twelve, a medical device company focused on the development of a transcatheter mitral valve replacement, or TMVR device. Twelve is the twelfth company spun out from the premier medical device incubator The Foundry. Medtronic has agreed to pay up to $458M for Twelve including $408M at closing and $50M on achievement of CE Marking. The cash- and debt-free transaction remains subject to customary closing conditions, and is expected to close in October 2015.
09:03 EDTJNJAcorda has major overhang removed by IPR denials, says Leerink
Subscribe for More Information
07:55 EDTKTWOK2M, Cooper favorite med tech names in current envirnoment, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien said that his favorite names in medical technology given the current environment of broader market weakness are K2M Group (KTWO) and Cooper Companies (COO) given their limited exposure to China and the fact that neither has large exposure to big capital equipment purchases or deferrable procedures nor are they in need of capital. O'Brien has Overweight ratings on both stocks.
07:32 EDTSYKStryker margins poised to increase, says Stifel
Subscribe for More Information
07:02 EDTNUVANuVasive exploring locations to build medical device facility
Subscribe for More Information
06:18 EDTJNJSears names Lynn Pendergrass as Hardlines president
Subscribe for More Information
August 24, 2015
08:29 EDTNUVAWilliam Blair to hold a field trip
Subscribe for More Information
August 21, 2015
09:01 EDTJNJ, SYKLeerink medical devices analyst holds an analyst/industry conference call
Medical Device Analyst Newitter, along with MEDACorp Specialists Dorance Dillon and Terence Farrell, discuss the Centers for Medicare & Medicaid Services' recently proposed "Comprehensive Care For Joint Replacement Payment Model" and how this model might influence ortho pricing and hospital-vendor relationships on an Analyst/Industry conference call to be held on August 24 at 1 pm.
August 20, 2015
11:33 EDTJNJLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
August 18, 2015
07:04 EDTNUVANuVasive appoints Johnson Lai as Chief Information Officer
Subscribe for More Information
05:49 EDTKTWOPiper highlights three in Med Tech with discounted valuations
Piper Jaffray analyst Matt O'Brien believes recent market volatility has created discounted valuations for three names in the Medical Technology space. K2M Group (KTWO), Invuity (IVTY) and SeaSpine (SPNE) have attractive valuations at current levels, O'Brien tells investors this morning in a research note. The analyst recommends "aggressively buying" shares of K2M, which he calls a misunderstood story that is under-owned by investors. The company continues to take market share and grow in the 16%-20% range, O'Brien writes. Invuity continues to win new accounts and has a unique sales rep model, he argues. In the case of SeaSpine, O'Brien says the company's valuation is one of the lowest he has seen in ten years for any spine company. The analyst has an Overweight rating on all three names.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use